Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

ee and twelve months ended December 31, 2009, respectively. Revenues totaled $44,000 and $0.3 million for the three- and twelve-month periods ended December 31, 2008, respectively. The revenues earned during 2009 resulted from the recognition of a portion of the upfront, non-refundable license fee and reimbursement of third-party development costs under our license agreement with Bayer. The $35.0 million upfront license fee has been recognized on a straight-line basis over a period of approximately 13 months, which was the original period in which we expected to complete all of our obligations under the license agreement with Bayer. In December 2009, we revised our estimate of this period extending it to 26 months as a result of design modifications to our ongoing RDEA119 clinical trials. The unamortized balance of the license fee as of the date of the change in estimate will be recognized over the revised timeline. The revenue earned in fiscal 2008 resulted from the research services we provided under our master services agreement with Valeant, which has since terminated by its terms.

The net loss applicable to common stockholders for the three and twelve months ended December 31, 2009 was $6.3 million and $30.9 million, or $0.34 per share and $1.70 per share, respectively, compared to a net loss applicable to common stockholders for the same periods in 2008 of $12.7 million and $5
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... and Markets ( http://www.researchandmarkets.com/research/63gppw/asian_dermatology ) has announced the ... by End User - Forecast to 2019" report to ... estimated to grow at a CAGR of 11.3% from 2014 ... share in the Dermatology devices market around 28.8% in 2014 ... Devices market holds a high potential for growth in future ...
(Date:5/1/2015)... 2015   Heska Corporation (NASDAQ: HSKA ... of advanced veterinary diagnostic and other specialty veterinary products ... will present at the 16th Annual B. Riley & Co. ... The conference will be held May 12-14, 2015 at Lowes ... management will be available during the day on May 13 ...
(Date:5/1/2015)... -- CytRx Corporation (CYTR), a biopharmaceutical research and development ... for the three months ended March 31, 2015, ... upcoming milestones for its clinical development programs. ... months of 2015, including the announcement of encouraging ... patients with soft tissue sarcoma, and positive interim ...
Breaking Medicine Technology:Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... IRVINE, Calif. , July 20 ... showing the ASP EVOTECH® Endoscope Cleaner and Reprocessor (ECR) ... required when using traditional AERs. Published in the July ... and simulated-use study was led by Michelle Alfa, Ph.D., ...
... , July 19 The law firm of Childers, Schlueter & ... involving the drug Reglan/metoclopramide will be held during the week of July ... al. in the United States District Court, Northern District of Georgia , ... The lawsuit alleges that ...
Cached Medicine Technology:Newly Published Data Demonstrate ASP EVOTECH® ECR Provides Cleaning That is Superior to Manual Cleaning of Flexible Endoscopes 2Newly Published Data Demonstrate ASP EVOTECH® ECR Provides Cleaning That is Superior to Manual Cleaning of Flexible Endoscopes 3Newly Published Data Demonstrate ASP EVOTECH® ECR Provides Cleaning That is Superior to Manual Cleaning of Flexible Endoscopes 4Newly Published Data Demonstrate ASP EVOTECH® ECR Provides Cleaning That is Superior to Manual Cleaning of Flexible Endoscopes 5Newly Published Data Demonstrate ASP EVOTECH® ECR Provides Cleaning That is Superior to Manual Cleaning of Flexible Endoscopes 6Childers, Schlueter & Smith, LLC Set for Reglan/metoclopramide Jury Trial Involving Woman's Development of Tardive Dyskinesia 2
(Date:5/2/2015)... May 02, 2015 As a ... issues of the face, neck and décolleté, radiofrequency ... with real potential for the success of vulvovaginal ... ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical ... ACGE, concluded that ThermiGyn’s temperature controlled radio frequency, ...
(Date:5/1/2015)... 02, 2015 The Venetian on Grace ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, like ... and attractive turquoise hues of Grace Bay Beach. ... percent of leisure travelers used their smartphones throughout the ... used in the planning and researching and continued through ...
(Date:5/1/2015)... RESTON, Va. (PRWEB) May 01, 2015 ... the nation’s leading nonprofit authority on the use of ... served as a key contributing resource to the United ... the use of electronically readable cards in Medicare. The ... Beneficiaries and Providers ” was released to the public ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
(Date:5/1/2015)... 01, 2015 As the sale of ... 18-month anniversary, many people in the industry are looking ... According the latest annual report by the ArcView ... in 2014, and reached nearly $3 billion in combined ... affair with cannabis, combined with the ongoing economic recovery, ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 2Health News:Colorado cannabis dispensary owner credits employees for successful “420” retail sales figures 3
... July 14 (HealthDay News) -- New research suggests that ... with other people could help them overcome anxiety and ... from Oxford University in the United Kingdom found that ... or negative interpretations of unclear social situations could influence ...
... Squibb today announced that the European Commission has approved ... previously-treated advanced melanoma. YERVOY, an innovative immunotherapy, ... advanced melanoma in a randomised, double-blind Phase III study ... June 2010.(1) Based on the survival (Kaplan-Meier) curve, ...
... of almost all cancer is influenced by environmental factors, ... title Cancer Risk Evaluation: Methods and Trends. However, while ... puts the vast majority of humans at risk regardless ... as hazardous working conditions, increase the cancer risk for ...
... Ca2+-dependent K+ channels) are essential for the regulation of ... neuronal excitability. New research shows that BK channel activation ... in the August 2011 issue of the ... research pointed to a possible unified theory of activation ...
... By Steven Reinberg HealthDay Reporter , ... have prostate cancer that,s considered "intermediate risk," radiation plus ... a new study finds. This combination of treatments, ... prostate cancer or advanced disease, the researchers said. Men ...
... young athletes collapsing during sports practice due to an ... health care professionals to call for mandatory electrocardiogram (ECG) ... validity of such a mandate. A new study ... Pediatrics examines the accuracy and effectiveness of pre-sport ...
Cached Medicine News:Health News:Training in Positive Thinking May Help Anxious Teens 2Health News:YERVOY (ipilimumab) approved for the treatment of previously treated advanced melanoma in the EU 2Health News:YERVOY (ipilimumab) approved for the treatment of previously treated advanced melanoma in the EU 3Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 2Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 3Health News:Sudden cardiac death in young athletes: Study suggests many ECG screenings are inaccurate 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: